US pharma tariffs of up to 100% finalised by Trump
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Newsletters and Deep Dive digital magazine
Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.
Editor's Picks
Newsletters and Deep Dive
digital magazine